Revamp Of Small Business Funding Scheme Set For Yet Another Delay By Congress
This article was originally published in The Pink Sheet Daily
Executive Summary
SBIR update: House and Senate can't agree in time on bill prized by cash-hungry biotech industry. End-of-January deadline is set to slide.
You may also be interested in...
Health Reform 101: Cashing In On Hidden Financial Aid Provisions
Biopharmas could win grants equivalent to half of their research expenses in 2009 and 2010, plus apply for a slice of the $500 million in new R&D funding available in areas of high medical need, courtesy of the health reform package
Health Reform 101: Cashing In On Hidden Financial Aid Provisions
Biopharmas could win grants equivalent to half of their research expenses in 2009 and 2010, plus apply for a slice of the $500 million in new R&D funding available in areas of high medical need, courtesy of the health reform package
SBIR reauthorization
Companies seeking Small Business Innovation Research program grant money could be majority-owned by venture capital outfits under the SBIR/STTR Reauthorization Act, S. 3362, approved by the Senate Committee on Small Business and Entrepreneurship July 30. A similar measure was passed by the full House on April 23 (1"The Pink Sheet," April 28, 2008, p. 27). Industry has complained that restrictions on SBIR grants for VC-funded firms detract from the value of the federal program that helps jump-start small company research. The Senate bill would allow no more than 18 percent of National Institutes of Health SBIR funds to go to firms that are majority-owned by venture capitalists